IDEXX EVP Nimrata Hunt sells 1,758 shares

IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share.

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Nimrata Hunt sold 1,758 shares of common stock in an open-market transaction on March 3, 2026 at a weighted average price of $634.5718 per share. After this sale, Hunt directly held 18,140.944 shares and indirectly held 160 shares jointly with a spouse.

According to a footnote, the weighted average sale price reflects individual trades executed between $634.5301 and $634.8201 per share.

Insider Trade Summary

Net Seller: 1,758 shares

Net Sell 2 txns

Insider Hunt Nimrata

Role Executive Vice President

Sold 1,758 shs ($1.12M)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,758	$634.5718	$1.12M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 18,140.944 shares (Direct); Common Stock — 160 shares (Indirect, jointly with spouse)

Footnotes (1)

1. F1. Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IDEXX (IDXX) shares did Nimrata Hunt sell in this Form 4?

Nimrata Hunt sold 1,758 shares of IDEXX Laboratories common stock. The transaction was reported as a non-derivative, open-market sale, reflecting a single aggregated amount of shares sold on March 3, 2026, according to the Form 4 data provided.

What price did Nimrata Hunt receive per IDEXX (IDXX) share in the sale?

The reported weighted average sale price was $634.5718 per share. A footnote explains this average reflects multiple trades, with individual prices ranging from $634.5301 to $634.8201 per share during the transaction on March 3, 2026.

What is Nimrata Hunt’s role at IDEXX (IDXX) in this insider filing?

Nimrata Hunt is identified as an Executive Vice President of IDEXX Laboratories. The Form 4 indicates Hunt is an officer of the company, not a director or ten percent owner, and the reported transaction involves company common stock.

How many IDEXX (IDXX) shares does Nimrata Hunt hold after the sale?

After the sale, Nimrata Hunt directly held 18,140.944 shares of IDEXX common stock. In addition, there are 160 shares reported as indirectly owned, held jointly with a spouse, reflecting total reported holdings across direct and indirect ownership.

What type of transaction is reported for Nimrata Hunt’s IDEXX (IDXX) shares?

The Form 4 shows an open-market sale of common stock, coded as a non-derivative transaction with transaction code “S.” The filing also notes a separate holding line for indirectly owned shares, without a specific buy or sell direction indicated.

How are Nimrata Hunt’s indirect IDEXX (IDXX) holdings characterized?

The filing lists 160 shares of IDEXX common stock as indirectly owned, described as held “jointly with spouse.” This indirect position is reported separately from the direct holdings and does not specify a particular transaction price or share change.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:01 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hunt Nimrata

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		S		1,758	D	$634.5718(1)	18,140.944	D
Common Stock								160	I	jointly with spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.